COM:STOKETHERAPEUTICS
Stoke Therapeutics
- Stock
Last Close
11.27
22/11 21:00
Market Cap
691.12M
Beta: -
Volume Today
240.61K
Avg: -
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|---|---|
average inventory | 5.47M - | 5.47M 0% | ||||||
average payables | 606K - | 911K 50.33% | 1.12M 23.27% | 1.94M 72.75% | 1.58M 18.79% | 1.23M 21.90% | ||
average receivables | 98K - | 238.50K 143.37% | 143.50K 39.83% | 69K 51.92% | 360K 421.74% | 326K 9.44% | ||
book value per share | -0.10 - | 4.47 4,522.12% | 12.49 179.45% | 8.54 31.59% | 5.93 30.61% | 4.75 19.83% | 0.00 99.92% | |
capex per share | -0.01 - | -0.04 349.94% | -0.09 128.77% | -0.03 65.54% | -0.03 4.17% | -0.10 211.85% | -0.00 99.96% | |
capex to depreciation | -1 - | -4.37 336.92% | -3.63 16.84% | -1.18 67.46% | -1.23 4.19% | -2.56 108.01% | -0.65 74.46% | |
capex to operating cash flow | 0.02 - | 0.09 306.32% | 0.05 38.26% | 0.02 52.76% | 0.02 27.88% | 0.12 593.23% | 0.02 83.97% | |
capex to revenue | -0.32 - | -0.18 42.37% | ||||||
cash per share | 0.14 - | 4.48 3,089.41% | 12.38 176.15% | 8.58 30.70% | 5.98 30.26% | 5.90 1.34% | 0.00 99.92% | |
days of inventory on hand | ||||||||
days payables outstanding | ||||||||
days sales outstanding | 17.30 - | 2.66 84.62% | ||||||
debt to assets | 0.01 - | 0.01 46.02% | ||||||
debt to equity | 0.01 - | 0.01 84.42% | ||||||
dividend yield | ||||||||
earnings yield | -0.02 - | -0.02 22.50% | -0.06 169.10% | -0.02 56.46% | -0.10 293.85% | -0.26 169.83% | -0.00 99.83% | |
enterprise value | 325.12M - | 495.80M 52.50% | 286.48M 42.22% | 1.79B 523.65% | 737.99M 58.69% | 247.83M 66.42% | 231.22B 93,199.80% | |
enterprise value over ebitda | -59.75 - | -39.45 33.98% | -8.03 79.65% | -33.68 319.47% | -8.57 74.54% | -2.37 72.30% | -2.01K 84,731.75% | |
ev to operating cash flow | -60.39 - | -45.22 25.11% | -9.22 79.60% | -42.32 358.72% | -11.03 73.93% | -7.78 29.49% | -2.85K 36,574.50% | |
ev to sales | 19.98 - | 26.34K 131,720.51% | ||||||
free cash flow per share | -0.43 - | -0.51 17.71% | -1.82 259.42% | -1.29 28.97% | -1.85 43.47% | -0.92 50.31% | -0.00 99.80% | |
free cash flow yield | -0.02 - | -0.02 17.71% | -0.06 224.52% | -0.02 67.52% | -0.08 270.37% | -0.10 29.14% | -0.00 99.64% | |
graham net net | -0.15 - | 4.38 2,998.14% | 12.15 177.15% | 8.23 32.30% | 5.41 34.21% | 4.22 21.96% | 0.00 99.93% | |
graham number | 0.99 - | 7.32 636.01% | 21.12 188.60% | 17.04 19.29% | 17.54 2.89% | 16.00 8.77% | 0.01 99.91% | |
income quality | 0.97 - | 0.88 9.61% | 0.96 9.71% | 0.81 15.88% | 0.78 3.52% | 0.32 59.56% | 0.77 145.57% | |
intangibles to total assets | 0 - | 0 | 0 | 0 | 0 | 0 | 0 | |
interest coverage | -717.21 - | -33.43 95.34% | -11.58 65.34% | |||||
interest debt per share | 0.04 - | 0.14 218.19% | 0.00 99.84% | |||||
inventory turnover | ||||||||
invested capital | 0.01 - | 0.01 84.42% | ||||||
market cap | 326.92M - | 601.20M 83.90% | 508.95M 15.34% | 2.07B 307.49% | 881.38M 57.50% | 359.02M 59.27% | 231.41B 64,356.24% | |
net current asset value | -1.82M - | 103.67M 5,793.14% | 221.71M 113.86% | 282.08M 27.23% | 208.13M 26.22% | 172.85M 16.95% | 146.56M 15.21% | |
net debt to ebitda | 0.33 - | 8.39 2,439.43% | 6.24 25.65% | 5.42 13.14% | 1.67 69.24% | 1.07 36.04% | 1.67 56.54% | |
net income per share | -0.43 - | -0.53 22.50% | -1.59 198.04% | -1.51 4.78% | -2.31 52.57% | -2.39 3.82% | -0.00 99.90% | |
operating cash flow per share | -0.42 - | -0.47 10.74% | -1.73 270.57% | -1.26 27.04% | -1.82 44.45% | -0.82 55.02% | -0.00 99.78% | |
payables turnover | ||||||||
receivables turnover | 21.10 - | 137.19 550.27% | ||||||
research and ddevelopement to revenue | 6.27 - | 9.37 49.26% | ||||||
return on tangible assets | -2.28 - | -0.12 94.89% | -0.12 7.10% | -0.17 36.23% | -0.35 108.76% | -0.36 2.53% | -0.46 26.10% | |
revenue per share | 0.32 - | 0.00 99.94% | ||||||
roe | 4.30 - | -0.12 102.77% | -0.13 6.65% | -0.18 39.20% | -0.39 119.87% | -0.50 29.49% | -0.66 30.26% | |
roic | 4.30 - | -0.12 102.89% | -0.14 12.97% | -0.18 28.05% | -0.38 114.24% | -0.51 31.79% | -0.72 41.83% | |
sales general and administrative to revenue | 3.14 - | 4.71 49.99% | ||||||
shareholders equity per share | -0.10 - | 4.47 4,522.12% | 12.49 179.45% | 8.54 31.59% | 5.93 30.61% | 4.75 19.83% | 0.00 99.92% | |
stock based compensation to revenue | 1.84 - | 2.88 56.14% | ||||||
tangible asset value | -1.29M - | 105.07M 8,232.20% | 224.43M 113.60% | 286.08M 27.47% | 217.78M 23.87% | 184.85M 15.12% | 159.56M 13.68% | |
tangible book value per share | -0.10 - | 4.47 4,522.12% | 12.49 179.45% | 8.54 31.59% | 5.93 30.61% | 4.75 19.83% | 0.00 99.92% | |
working capital | -1.80M - | 103.68M 5,843.82% | 221.93M 114.06% | 282.50M 27.29% | 212.08M 24.93% | 212.68M 0.28% | 184.52M 13.24% |
All numbers in (except ratios and percentages)